Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB-1303 vs Chemotherapy in HER2-Low, HR+ Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337Phase 3Active, not recruiting
- Sponsor
- Duality Biotherapeutics
- Start
- Jan 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 17
01
Overview
A Phase 3 trial of trastuzumab pamirtecan in breast cancer, sponsored by Duality Biotherapeutics. Started Jan 2024; status: active, not recruiting.
02
Drugs
trastuzumab pamirtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06018337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06018337.